Sandoz Group (OTCMKTS:SDZNY) Downgraded by Royal Bank Of Canada to “Hold”

Royal Bank Of Canada downgraded shares of Sandoz Group (OTCMKTS:SDZNY) from a moderate buy rating to a hold rating in a research report report published on Monday morning,Zacks.com reports.

Other research analysts have also recently issued reports about the stock. Jefferies Financial Group raised shares of Sandoz Group from a “hold” rating to a “strong-buy” rating in a report on Thursday, February 12th. Barclays lowered Sandoz Group from a “strong-buy” rating to a “hold” rating in a report on Thursday, February 26th. One analyst has rated the stock with a Strong Buy rating and two have assigned a Hold rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy”.

Sandoz Group Price Performance

SDZNY stock opened at $76.57 on Monday. Sandoz Group has a 12-month low of $35.61 and a 12-month high of $94.15. The stock’s 50 day simple moving average is $81.48 and its 200 day simple moving average is $71.82. The company has a quick ratio of 0.82, a current ratio of 1.29 and a debt-to-equity ratio of 0.62.

About Sandoz Group

Sandoz Group (OTCMKTS:SDZNY) is a multinational pharmaceutical company focused on the development, manufacturing and commercialization of generic medicines and biosimilars. The company supplies off-patent small-molecule drugs as well as biologic alternatives intended to offer lower-cost therapeutic options across a range of clinical areas. Sandoz emphasizes access and affordability, positioning its portfolio to serve hospitals, pharmacies and health systems looking to expand patient access to essential therapies.

The company’s product offerings span conventional generics, complex and specialty generics, and a growing pipeline of biosimilar medicines.